版本:
中国

BRIEF-Delmar Pharmaceuticals provides VAL-083 updates from ongoing American Association For Cancer Research annual meeting

April 5 Delmar Pharmaceuticals Inc:

* Delmar pharmaceuticals provides val-083 updates from the ongoing American Association For Cancer Research (AACR) annual meeting

* Delmar Pharmaceuticals Inc - VAL-083 is active in cells with t790m and KRAS mutations indicating that agent can overcome TKI-resistance

* Delmar Pharma- poster demonstrates that val-083 has differentiated moa with a dual signaling pathway to cause permanent DNA damage in NSCLC cell lines Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐